Bill intelligence
S. 5004, Patient Cost-Sharing Parity Mandate. Quorum's AI analysis reads it as a net benefit — and names who gains.
S. 5004 · Net good
Health Insurance Reform
What it does
This bill requires health insurance plans to charge patients the same out-of-pocket costs (copays, deductibles, coinsurance) for oral cancer drugs taken at home as they do for intravenous cancer drugs administered in a doctor's office.
The analysis names oral anticancer drug manufacturers — and 1 more group — among the beneficiaries.
The trade-off
Oral cancer drugs may become more attractive to patients due to lower cost-sharing, potentially shifting demand away from intravenous formulations and affecting infusion center utilization and revenue.
Transparency scores 85%, with a medium warning level and no detached riders.
Who is behind it
Filed by Tina Smith. Cosponsored by Jerry Moran.
Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
SOURCE: QUORUM BILL ANALYSIS (LLM, FULL TEXT) · QUORUM BILL TRANSPARENCY ANALYSIS